Navigation

nedocromil ophthalmic (Alocril)

 

Classes: Mast Cell Stabilizers, Ophthalmic

Dosing and uses of Alocril (nedocromil ophthalmic)

 

Adult dosage forms and strengths

ophthalmic solution

  • 2%

 

Allergic Conjunctivitis

Instill 1-2 gtt in each eye BID throughout period of exposure (ie, until pollen season is over or offending allergen terminated)

 

Pediatric dosage forms and strengths

ophthalmic solution

  • 2%

 

Allergic Conjunctivitis

<3 years: Safety and efficacy not established

3 years or older: As adults; instill 1-2 gtt in each eye BID throughout period of exposure (ie, until pollen season is over or offending allergen terminated)

 

Alocril (nedocromil ophthalmic) adverse (side) effects

>10%

Headache (40%)

Ocular burning/stinging (10-30%)

Unpleasant taste (10-30%)

Nasal congestion (10-30%)

 

1-10%

Asthma

Conjunctivitis

Eye redness

Photophobia

Rhinitis

 

Warnings

Contraindications

Hypersensitivity

 

Cautions

Refrain from wearing contacts while exhibiting symptoms of allergic conjunctivitis

Avoid contact with tip of dispenser to prevent contamination

 

Pregnancy and lactation

Pregnancy category: B

Lactation: Unknown whether distributed in breast milk, do not nurse

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of Alocril (nedocromil ophthalmic)

Absorption: Low systemic absorption; <4% via nasolacrimal duct

Metabolism: Not metabolized

Excretion (as unchanged drug): feces (30%), urine (70%)

 

Mechanism of action

Mast cell stabilizer; inhibits release of cell mediators in response to allergen; decreases chemotaxis and eosinophil activation